Cellectis S.a. share price logo

Cellectis S.a. Share Price

NASDAQ: CLLS

Small Cap

$3.13

+0.14

(+4.68%)

Live

as on

Cellectis S.a. Stock Performance

as on September 16, 2025 at 10:35 pm IST

  • Day's Low

    Day's High

    $3.05
    $3.2
    downward going graph

    2.56%

    Downside

    2.24%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.1
    $3.35
    downward going graph

    64.86%

    Downside

    7.03%

    Upside

    downward going graph

Cellectis S.a. share price movements today

Previous Close
$2.99
Open
$3.16
Volume
223.7K
Day's Low - High
$3.05 - $3.2
52 Week Low - High
$1.1 - $3.35

Cellectis S.a. Historical Returns

1 Month Return
+ 4.91 %
3 Month Return
+ 115.88 %
1 Year Return
+ 30 %
3 Year Return
-5.97 %
5 Year Return
-85.25 %

Cellectis S.a. Stock Fundamentals & Key Indicators

Check Cellectis S.a. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$327.6M

EPS (TTM)

-0.61

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

P/B Ratio

0

PEG Ratio

0

EBITDA

-33.0M

Revenue (TTM)

63.4M

Profit Margin

-93.00%

Return On Equity TTM

82450700.00%

Cellectis S.a. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cellectis S.a. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Cellectis S.a. image
Cellectis S.a.
BUY$327.6M-85.25%NA-93.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$61.1B251.26%-505.15-12.96%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$38.7BNANA-3.89%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$101.2B47.46%28.0931.86%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$59.6B0.6%14.131.37%

Stock Returns calculator for Cellectis S.a. Stock including INR - Dollar returns

The Cellectis S.a. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Cellectis S.a. investment value today

Current value as on today

₹1,40,954

Returns

₹40,954

(+40.95%)

Returns from Cellectis S.a. Stock

₹36,087 (+36.09%)

Dollar Returns*

₹4,867 (+4.87%)

Analyst Recommendation on Cellectis S.a. Stock

Based on 14 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 14 analysts, 85.71% of analysts recommend a 'BUY' rating for Cellectis S.a.. Average target price of $5.6

Cellectis S.a. Share Price Target

Get share price movements and forecasts by analysts on Cellectis S.a..

What analysts predicted

44.11%UPSIDE

Target Price

$5.6

Current Price

$3.13

Analyzed by

14 Analysts

Target

$5.60

Cellectis S.a. target price $5.6, a slight upside of 44.11% compared to current price of $3.13. According to 14 analysts rating.

Cellectis S.a. Stock's Interest Amongst Investors

Search interest for Cellectis S.a. Stock has decreased by -75% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-75% versus previous 30 day period

Cellectis S.a. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
0
0
0
0
4
8
16
12
10
16
Gross Profit
0
0
0
-5
0
3
11
10
8
11
Operating Income
-23
-23
-20
-30
-22
-23
-12
-10
-14
-11
EBITDA
-21
-21
-12
-41
9
-20
-18
12
-11
-18
Interest Expense
5
16
1
1
1
1
2
1
1
2
Depreciation
4
4
4
5
4
4
4
5
4
5
Income Before Tax
-27
-7
-17
-64
3
-26
-24
6
-18
-25
Income Tax Expense
2
0
0
0
-2
-1
-1
0
0
-1
Net Income
-30
-10
-17
-42
5
-25
-23
5
-18
-24
Net Profit Margin
-21635.97%
-5982.02%
-11278.71%
-15145.58%
124.62%
-313.48%
-142.32%
46.57%
-170.14%
-141.92%

Cellectis S.a. Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
55
42
25
12
15
73
73
19
0
41
Gross Profit
52
40
22
9
3
37
37
17
0
21
Operating Income
-30
-63
-92
-105
-123
-85
-85
-89
-106
-59
EBITDA
-26
-65
-108
-102
-116
-75
-68
-71
-92
-15
Interest Expense
0
0
0
0
2
12
5
3
6
7
Depreciation
-
-
3
2
6
9
16
18
18
19
Income Before Tax
-22
-63
-103
-88
-115
-97
-97
-98
-123
-43
Income Tax Expense
0
-1
-13
16
-24
-24
-11
0
-6
-6
Net Income
-22
-63
-99
-78
-90
-72
-86
-98
-101
-36
Net Profit Margin
-40.81%
-150.10%
-394.51%
-618.12%
-597.01%
-98.14%
-116.68%
-514.78%
-13385.30%
-88.57%

Cellectis S.a. Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-7
-17
-61
5
-25
-23
5
-18
-24
Operating Cash Flow
-19
-17
39
-23
52
-5
0
-17
-10
Investing Cash Flow
-1
0
-13
-2
-106
22
-16
4
-
Financing Cash Flow
19
1
41
12
78
-4
2
-4
-4
Change in Cash
-1
-17
69
-13
26
10
-15
-15
-67

Cellectis S.a. Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-63
-103
-88
-115
-97
-125
-98
-116
-36
Operating Cash Flow
-31
-52
-68
-69
-80
-104
-87
-24
22
Investing Cash Flow
-50
1
35
-35
-54
7
-2
-15
-102
Financing Cash Flow
0
41
236
-3
27
47
1
82
89
Change in Cash
-76
1
195
-110
-99
-55
-92
43
6

Global Institutional Holdings in Cellectis S.a.

Funds
Holdings
UBS Asset Mgmt Americas Inc
4.71%
Long Focus Capital Management, LLC
4.7%
B Group, Inc
3.25%
Macquarie Group Ltd
0.23%
Millennium Management LLC
0.1%
See all

Insights on Cellectis S.a.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, CLLS stock has moved up by 115.9%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 10.65M → 16.93M (in $), with an average increase of 37.1% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.5% return, outperforming this stock by 122.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 70.6% return, outperforming this stock by 40.6%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 5.92M → -24.03M (in $), with an average decrease of 219.4% per quarter

About Cellectis S.a.

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
OrganisationCellectis S.a.
Headquarters8, rue de la Croix Jarry, Paris, France, 75013
IndustryHealth Technology
CEODr. Andre Choulika Ph.D.
E-voting on sharesClick here to vote

Key Management of Cellectis S.a.

Name

Title

Mr. Arthur Stril

CFO & Chief Business Officer

Valerie Cros

Principal Financial Officer & Principal Accounting Officer

Mr. Jean Charles Epinat Ph.D.

Chief Technological Officer

Dr. Philippe Duchateau Ph.D.

Chief Scientific Officer

Pascalyne Wilson

Director of Communications

Mr. Stephan Reynier M.Sc.

Chief Regulatory & Pharmaceutical Compliance Officer

Dr. David J. Sourdive Ph.D.

Co-Founder, Deputy CEO, Executive VP of CMC & Manufacturing and Director

Ms. Marie-Bleuenn Terrier

General Counsel & Secretary of the Board of Directors

Ms. Kyung Nam-Wortman

Executive VP & Chief Human Resources Officer

Dr. Andre Choulika Ph.D.

Co-Founder, CEO & Director

FAQs

What is Cellectis S.a. share price today?

Cellectis S.a. share price today is $3.13 as on . Cellectis S.a. share today touched a day high of $3.2 and a low of $3.05.

What is the 52 week high and 52 week low for Cellectis S.a. share?

Cellectis S.a. share touched a 52 week high of $3.35 on and a 52 week low of $1.1 on . Cellectis S.a. stock price today i.e. is trending at $3.13,which is 6.57% down from its 52 week high and 184.55% up from its 52 week low.

What is Cellectis S.a.'s market capitalisation today?

Cellectis S.a. market capitalisation is $0.00T as on .

How to invest in Cellectis S.a. Stock (CLLS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Cellectis S.a. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cellectis S.a. Shares that will get you 0.4792 shares as per Cellectis S.a. share price of $3.13 per share as on September 16, 2025 at 10:35 pm IST.

What is the minimum amount required to buy Cellectis S.a. Stock (CLLS) from India?

Indian investors can start investing in Cellectis S.a. (CLLS) shares with as little as ₹88.042 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹880.42 in Cellectis S.a. stock (as per the Rupee-Dollar exchange rate as on ). Based on Cellectis S.a. share’s latest price of $3.13 as on September 16, 2025 at 10:35 pm IST, you will get 3.1949 shares of Cellectis S.a.. Learn more about fractional shares .

What are the returns that Cellectis S.a. has given to Indian investors in the last 5 years?

Cellectis S.a. stock has given -85.25% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?